Xenon Pharmaceuticals Inc. Stock
Xenon Pharmaceuticals Inc. Stock price
Key metrics
| Market capitalization | $2.25b |
| Enterprise Value | $1.63b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.98 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-279.30m |
| Free Cash Flow (TTM) Free Cash Flow | $-180.71m |
| Cash position | $626.91m |
Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
Xenon Pharmaceuticals Inc. Stock Analysis
Analyst Opinions
17 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:
Analyst Opinions
17 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:
Financial data from Xenon Pharmaceuticals Inc.
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -2.56 -2.56 |
28%
28%
|
|
| EBITDA | -277 -277 |
31%
31%
|
EBIT (Operating Income) EBIT | -279 -279 |
30%
30%
|
| Net Profit | -234 -234 |
28%
28%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xenon Pharmaceuticals Inc. Stock News
Company Profile
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
| Head office | Canada |
| CEO | Ian Mortimer |
| Employees | 327 |
| Founded | 1996 |
| Website | www.xenon-pharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
